Despite pipeline setbacks and slow CASGEVY rollout, future revenue acceleration and expansion into cardiovascular and autoimmune diseases offer significant long-term growth opportunities. CRISPR ...
CRISPR Therapeutics has an approved gene-therapy treatment still in its early growth stages. The company isn't profitable, but has a strong cash position, which can help buy a lot of time. One of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results